Effect of sevoflurane on serum CK-MB levels after percutaneous coronary stent placement: A prospective randomized clinical trial

OBJECTIVES. Markers of myocardial injury, such as creatine kinase-myocardial band (CK-MB) mass, are elevated in up to 30% of patients undergoing percutaneous coronary intervention (PCI) with stent deployment. This elevation represents myocardial injury that can impact the patient in the long term, including the risk of death. Sevoflurane, an inhaled anesthetic, may have cardioprotective properties that benefit patients undergoing PCI. The primary objective was to compare serum CK-MB mass raise in patients who received sevoflurane to those who received a placebo prior to PCI. METHODS. We enrolled patients with coronary artery disease who were eligible for PCI in a randomized (1:1), double-blind, placebo-controlled trial; patients having experienced acute myocardial infarction within 72 hours and those with saphenous vein graft stenting were excluded. Patients (n = 1254) were randomized to receive sevoflurane (2% inspired fraction) or placebo (oxygen alone) for 30 minutes prior to PCI. Additionally, we compared substantial elevations in CK-MB mass (defined as >5x the upper limit of normal), length of stay in the intensive care unit and in-hospital, and 1-year mortality. RESULTS. Sevoflurane was unable to promote cardioprotection, as determined by CK-MB mass levels (sevoflurane group: 2.52 ± 9.64; control group: 1.84 ± 8.58; P=.32). No effect was noticed on the reduction among patients who (AQ: with?) increase (AQ: increased?) marker levels (prevalence of increase in CK-MB mass greater than the upper limit of normality was 30.8% in the sevoflurane group and 28.9% in the control group; P=.33; 4.6% vs 3.1%, respectively, for increases 5x above the upper limit of normality [P=.21]). CONCLUSIONS. Sevoflurane failed to reduce myocardial injury after PCI. Therefore, its usage should not be routinely recommended.

Effect of sevoflurane on serum CK-MB levels after percutaneous coronary stent placement: A prospective randomized clinical trial.

OBJECTIVES: Markers of myocardial injury, such as creatine kinase-myocardial band (CK-MB) mass, are elevated in up to 30% of patients undergoing percutaneous coronary intervention (PCI) with stent deployment. This elevation represents myocardial injury that can impact the patient in the long term, including the risk of death. Sevoflurane, an inhaled anesthetic, may have cardioprotective properties that benefit patients undergoing PCI. The primary objective was to compare serum CK-MB mass raise in patients who received sevoflurane to those who received a placebo prior to PCI. METHODS: We enrolled patients with coronary artery disease who were eligible for PCI in a randomized (1:1), double-blind, placebo-controlled trial; patients having experienced acute myocardial infarction within 72 hours and those with saphenous vein graft stenting were excluded. Patients (n = 1254) were randomized to receive sevoflurane (2% inspired fraction) or placebo (oxygen alone) for 30 minutes prior to PCI. Additionally, we compared substantial elevations in CK-MB mass (defined as >5x the upper limit of normal), length of stay in the intensive care unit and in-hospital, and 1-year mortality. RESULTS: Sevoflurane was unable to promote cardioprotection, as determined by CK-MB mass levels (sevoflurane group: 2.52 ± 9.64; control group: 1.84 ± 8.58; P=.32). No effect was noticed on the reduction among patients who (AQ: with?) increase (AQ: increased?) marker levels (prevalence of increase in CK-MB mass greater than the upper limit of normality was 30.8% in the sevoflurane group and 28.9% in the control group; P=.33; 4.6% vs 3.1%, respectively, for increases 5x above the upper limit of normality [P=.21]). CONCLUSIONS: Sevoflurane failed to reduce myocardial injury after PCI. Therefore, its usage should not be routinely recommended.

Routine ultrasound-guided femoral access and use of one vascular closure device for femoral hemostasis after TAVR: feasibility and safety

INTRODUCTION: The transfemoral TAVR is a safe and effective treatment for severe and symptomatic aortic stenosis, regardless of the surgical risk profile. The vascular access and hemostasis are fundamental steps of the procedure and have impact on the prognosis. Traditionally, the arterial hemostasis has been obtained through the use of 2 or more vascular closure devices (ProGlide, Perclose) or the association of vascular closure devices (suture + collagen). Nevertheless, the reduction of sheet size and routinary use of ultrasound guided puncture, the use of one vascular closure device could be effective in obtaining hemostasis in such patients. METHODS: Observational, prospective study, including patients submitted to transfemoral TAVR through March/2020 to April/2022. The arterial access was obtained with ultrasound assistance on all cases. From September/2021 we initiated the institutional protocol with the use of one Perclose after obtaining the femoral access (pre-closure technique). We evaluated the need for additional vascular closure devices, the presence of femoral stenosis of > 50% (according to femoral angiography at the end of the procedure) and the occurrence of bleeding (according to the VARC-III criteria). RESULTS: In the period, a total of 75 patients were submitted to transfemoral TAVR on our institution. We used 1 Perclose in 31 patients (Group A) and 2 Perclose devices on 44 patients (Group B). The characteristics of the patients at baseline; mean age of 77 7.32 years, 39% were female, and mean STS score of 3.6%. There were no significant differences between Group A and B. Balloon expandable TAVR was used in 97.3% of the patients, and in 96% of the patients the introducer sheet used was 14F. At the post-procedure femoral angiography, residual stenosis was present in only 1 (4.1%) patient on Group A and on 9 (25%) patients on Group B (p=0.034). there was no difference in major or minor bleeding with manual prolonged compression in both groups. two patients in Group A required additional vascular closure devices and no in group B. CONCLUSION: On this initial series, the ultrasound guided femoral access and the use of one vascular closure device, proved to be feasible and effective on vascular hemostasis, while reducing residual stenosis of the femoral artery when compared to the use of two vascular closure devices.

Artéria Coronária Direita Originada da Artéria Descendente Anterior: Uma Rara Anomalia Coronariana / Anomalous Origin of the Right Coronary Artery from the Mid-Left Anterior Descending Artery: A Rare Coronary Anomaly

A artéria coronária única é anomalia rara, que pode estar associada à isquemia miocárdica e morte súbita. Apresentamos o caso de uma mulher jovem, com quadro de angina atípica, cujo cateterismo revelou artéria coronária direita que se originava do terço médio da artéria descendente anterior, uma variante da artéria coronária única.

A single coronary artery is a rare anomaly that may be associated with myocardial ischemia and sudden death. We present a case of a young woman with atypical angina whose coronary angiography revealed a right coronary artery originating from the mid left anterior descending artery, a variant of the single coronary artery.